The Ministry of Food and Drug Safety (MFDS) stated that on May 29th, it has granted approval of the orphan drug 'Pluvicto inj (Lutetium(177Lu) Vipivotide Tetraxetan)' for the treatment of prostate cancer. Pluvicto is imported by Novartis Korea.

It is a radioligand therapy comprised of radioisotope Lutetium(177Lu), which binds to prostate-specific membrane antigen (PSMA), commonly expressed in prostate cancer, delivering therapeutic radiation to prostate cancer, leading to cell death of cancer cells.

Pluvicto inj has been approved for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inh